[go: up one dir, main page]

MXPA04004266A - Uso de il-19, il-22 e il-24 para tratar trastornos hematopoyeticos. - Google Patents

Uso de il-19, il-22 e il-24 para tratar trastornos hematopoyeticos.

Info

Publication number
MXPA04004266A
MXPA04004266A MXPA04004266A MXPA04004266A MXPA04004266A MX PA04004266 A MXPA04004266 A MX PA04004266A MX PA04004266 A MXPA04004266 A MX PA04004266A MX PA04004266 A MXPA04004266 A MX PA04004266A MX PA04004266 A MXPA04004266 A MX PA04004266A
Authority
MX
Mexico
Prior art keywords
hematopoietic disorders
treat hematopoietic
treat
disorders
mammalian
Prior art date
Application number
MXPA04004266A
Other languages
English (en)
Inventor
William Rowlinson Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04004266A publication Critical patent/MXPA04004266A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a un procedimiento de uso de una secuencia de genes de mamifero y polipeptidos codificados por los mismos para tratar trastornos hematopoyeticos en mamiferos.
MXPA04004266A 2001-11-06 2002-10-24 Uso de il-19, il-22 e il-24 para tratar trastornos hematopoyeticos. MXPA04004266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33298601P 2001-11-06 2001-11-06
PCT/US2002/031599 WO2003089569A2 (en) 2001-11-06 2002-10-24 Use of il-19, il-22 and il-24 to treat hematopoietic disorders

Publications (1)

Publication Number Publication Date
MXPA04004266A true MXPA04004266A (es) 2004-07-08

Family

ID=29250436

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004266A MXPA04004266A (es) 2001-11-06 2002-10-24 Uso de il-19, il-22 e il-24 para tratar trastornos hematopoyeticos.

Country Status (7)

Country Link
US (1) US20050054567A1 (es)
EP (1) EP1511511A4 (es)
JP (1) JP2005519986A (es)
AU (1) AU2002367534A1 (es)
CA (1) CA2466229A1 (es)
MX (1) MXPA04004266A (es)
WO (1) WO2003089569A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
MXPA06006377A (es) * 2003-12-03 2006-08-23 Schering Corp Metodos para modular la actividad de citocina y reactivos relacionados.
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
JP6105289B2 (ja) * 2010-02-22 2017-03-29 ユニベルシテ ピエール エ マリー キュリー（パリ シズエム） 造血系列の細胞を増殖及び分化させる細胞培養培地
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
JP7356994B2 (ja) 2018-03-02 2023-10-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 網膜炎症および神経変性を処置するためのｉｌ－３４の使用
EP4090381A1 (en) 2020-01-17 2022-11-23 The United States of America, as represented by the Secretary, Department of Health and Human Services <smallcaps/>? ? ?crx-? ? ? ? ?gene therapy for treatment ofautosomal dominant retinopathies
CN111228467A (zh) * 2020-03-11 2020-06-05 白晓春 白介素19在制备治疗中性粒细胞减少症药物中的应用
EP4301777A1 (en) * 2021-03-02 2024-01-10 Dana-Farber Cancer Institute, Inc. Methods of treating red blood cell disorders
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
AU4208799A (en) * 1998-05-29 1999-12-13 Human Genome Sciences, Inc. Interleukins-21 and 22

Also Published As

Publication number Publication date
CA2466229A1 (en) 2003-10-30
JP2005519986A (ja) 2005-07-07
EP1511511A4 (en) 2006-03-29
WO2003089569A3 (en) 2005-01-13
AU2002367534A1 (en) 2003-11-03
EP1511511A2 (en) 2005-03-09
US20050054567A1 (en) 2005-03-10
WO2003089569A2 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
MXPA04004266A (es) Uso de il-19, il-22 e il-24 para tratar trastornos hematopoyeticos.
WO2005007818A3 (en) Exo-specific amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof
TR200100056T2 (tr) Nörotrofik faktörler
MXPA02004666A (es) Gelatinas recombinantes.
WO2003054152A3 (en) Novel nucleic acids and polypeptides
EP2039762A3 (en) Nitralases
WO2004080148A3 (en) Novel nucleic acids and polypeptides
AU2002236300A1 (en) Novel protein, gene encoding the same and method of using the same
TW200611910A (en) Interferon-alpha polypeptides and conjugates
AU2000244105A1 (en) Cloning and expressing an acid-resistant extracellular lipase of yarrowia lipolytica
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
AU2001263269A1 (en) Long wavelength engineered fluorescent proteins
ATE333520T1 (de) Neuartige polynukleotide und polypeptide des ifnalpha-21 gens
AU2002365909A1 (en) Glycosidases, nucleic acids encoding them and methods of making and using them
WO2003080795A3 (en) Novel nucleic acids and secreted polypeptides
AU2002304249A1 (en) Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
AU1719497A (en) An enzyme with pectin esterase activity
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2003025142A3 (en) Novel nucleic acids and secreted polypeptides
AU2002334950A1 (en) T. reesei phytase enzymes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
WO2004053052A3 (en) HUMAN RECOMBINANT ENDOOLIGOPEPTIDASE A (hEOPA)
AU3667397A (en) Recombinant n-proteinase, and the production, methods and uses thereof
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8
AU2001268108A1 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal